Navigation Links
Sinapis Pharma Completes Phase I Trial
Date:7/11/2011

JACKSONVILLE, Fla., July 11, 2011 /PRNewswire/ -- Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.  The Phase I trial entitled " A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetics of Oral and Intravenous Administration of Methamphetamine Hydrochloride in Healthy Volunteers" was conducted at Prism Research in St. Paul, MN.

This was a single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover study of the safety and pharmacokinetics of oral and IV administration of methamphetamine HCl in six healthy volunteers.  Subjects were randomized 1:1 to receive a single oral dose of methamphetamine HCl (5 mg Desoxyn® tablet) or a single IV dose of methamphetamine HCl (5 mL of 0.5 mg/mL methamphetamine HCl injection infused over one hour for a total dose of 2.5 mg), and then crossed over to the other treatment (i.e., IV or oral dose, respectively) after a 10 day washout period.  Subjects received a single dose of study drug on Day 1 of each of the two treatment periods.

The trial successfully demonstrated the safety of an IV infusion of Methamphetamine and produced the IV infusion pharmacokinetics needed to initiate Phase IIa clinical studies in stroke patients.

Sinapis plans to initiate its Phase IIa trial in stroke patients before year end.

Dr Donald Picker, Sinapis CEO, said  "We are very pleased  and excited to complete the next step in the development of this drug for stroke and traumatic brain injury patients. We are eager to begin the proof of principle trials in these very important indications where there are currently no effective treatments."

Sinapis Pharma, Inc. (www.sinapispharma.com) is an early stage biotechnology company whose lead compound methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models.


'/>"/>
SOURCE Sinapis Pharma, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
2. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
3. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
4. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
5. PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation
6. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
7. Genesis Biopharma Conference Call and Webcast Reminder
8. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
9. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
10. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
11. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... States (PRWEB) , ... September 22, 2017 , ... ... for venous leg ulcers is now being assessed in clinical trials in the ... trial please talk to your nurse or physician or find your nearest participating ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief ... NV on September 27th. His presentation is at 12:10pm in the Probiotics Resource Center, ... present at SupplySide West and discuss how probiotics have shown impressive data in areas ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Each relaunch of the portal includes new features that facilitate streamlined and compliant ... seek to remain at the forefront of medical advancements, they rely on efficiencies ...
(Date:9/21/2017)... ... September 21, 2017 , ... Today, BioPharma Institute, a ... the addition of 5 new courses to its prospectus. These include the eagerly-awaited ... CFR Part 11 on Electronic Records and Electronic Signatures (Part 11 of Title ...
Breaking Biology Technology:
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
Breaking Biology News(10 mins):